References:
1. Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Cancer Epidemiol 2022;79.
2. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016;34(23):2712-2720.
3. Kirkim G, Olgun Y, Aktas S, Kiray M, Kolatan E, Altun Z, et al. Is there a gender-related susceptibility for cisplatin ototoxicity? Eur Arch Oto-Rhino-Laryngol 2015;272(10):2755-2763.
4. El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC, Jr., et al. Clinical and genome-wide analysis of cisplatininduced tinnitus implicates novel ototoxic mechanisms. Clin Cancer Res 2019;25(13):4104-4116.
5. Coling DE, Ding D, Young R, Lis M, Stofko E, Blumenthal KM, et al. Proteomic analysis of cisplatin-induced cochlear damage: Methods and early changes in protein expression. Hear Res 2007;226(1-2):140-156.
6. Bielefeld EC, Gonzalez A, DeBacker JR. Changing the time intervals between cisplatin cycles alter its ototoxic side effect. Hear Res 2021;404.
7. Chan SL, Ng LS, Goh X, Siow CH, Goh HL, Goh BC, et al. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. Head Neck 2018;40(7):1425-1433.
8. Miaskowski C, Paul SM, Mastick J, Abrams G, Topp K, Smoot B, et al. Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors. J Pain Symptom Manage 2018;56(1):88-97.
9. Gentilin E, Simoni E, Candito M, Cazzador D, Astolfi L. Cisplatin-Induced Ototoxicity: Updates on Molecular Targets. Trends Mol Med 2019;25(12):1123-1132.
10. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, et al. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm 2021;163:60-71.
11. Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun 2017;8(1).
12. Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Oto-Rhino-Laryngol 2017;274(3):1187-1196.
13. Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM, et al. Predicting Hearing Loss after Radiotherapy and Cisplatin Chemotherapy in Patients with Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 2020;146(2):106-112.
14. Ardeshirrouhanifard S, Fossa SD, Huddart R, Monahan PO, Fung C, Song Y, et al. Ototoxicity after Cisplatin-Based Chemotherapy: Factors Associated with Discrepancies between Patient-Reported Outcomes and Audiometric Assessments. Ear Hear 2022;43(3):794-807.
15. Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health 2020;4(2):141-150.
16. Desilets A, Adam J-, Res DS. Management of cisplatin-associated toxicities in bladder cancer patients. Curr Opin Support Palliat Care 2020;14(3):286-292.
17. Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH, et al. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Survivorship 2018;12(2):234-245.
18. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
19. Higgins JPT, Savović J, Page MJ, et al. Chapter 8: Assessing risk of bias in a randomized trial. In: Cochrane Handbook for systematic reviews of interventions version 6.2. Cochrane,
2021. www.training.cochrane.org/handbook
20. Wells GASB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2016) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https ://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
21. Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC methods programme, 2006.
22. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995;13(2):490-496.
23. Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang L, Raschko JW, et al. Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 1995;13(5):1231-1237.
24.Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14(7):2101-2112.
25.Planting AST, Catimel G, De Mulder PHM, De Graeff A, Höppener F, Verweij J, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 1999;10(6):693-700.
26. Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, et al. High-dose cisplatin with amifostine: Ototoxicity and pharmacokinetics. Laryngoscope 2004;114(9 I):1660-1667.
27. Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. ARCH OTOLARYNGOL HEAD NECK SURG 1997;123(9):978-981.
28. Ishikawa E, Sugimoto H, Hatano M, Nakanishi Y, Tsuji A, Endo K, et al. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer. Acta Oto-Laryngol 2015;135(9):919-924.
29. Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, et al. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. Otol Neurotol 2021;42(5):678-685.
30.Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007;25(24):3759-3765.
31.Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I, et al. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. J Otolaryngol Head Neck Surg 2019;48(1).
32. Yildirim M, Inançli HM, Samanci B, Oktay MF, Enöz M, Topçu I. Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate. Kulak Burun Bogaz Ihtis Derg 2010;20(4):173-183.
33.Riga MG, Chelis L, Kakolyris S, Papadopoulos S, Stathakidou S, Chamalidou E, et al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: A feasible method with promising efficacy. Am J Clin Oncol Cancer Clin Trials 2013;36(1):1-6.
34. Yoo J, Hamilton SJ, Angel D, Fung K, Franklin J, Parnes LS, et al. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: A pilot randomized study in head and neck cancer patients. Laryngoscope 2014;124(3):E87-E94.
35. Marshak T, Steiner M, Kaminer M, Levy L, Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: A randomized controlled study. Otolaryngol Head Neck Surg 2014;150(6):983-990.
36.Moreno I, Belinchon A. Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial. Ear Hear 2022;43(2):676-684.
37. Nasr W, Abdelhady M, Abd Elbary M, Nada E. Treatment of cisplatin-induced ototoxicity by intra-tympanic corticosteroid injection. Indian J Otol 2018;24(1):33-37.
38. Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, et al. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur J Cancer 2017;87:75-83.
39. Delarestaghi MM, Mohebbi S, Basi A, Rahbar N, Karbasi Z, Karbasi H. The Protective Effect of Sertraline in Preventing Cisplatin-induced Ototoxicity in Solid Organ Chemotherapy. Int Tinnitus J 2018;22(2):175-180.
40. Fernandez KA, Allen P, Campbell M, Page B, Townes T, Li C-, et al. Atorvastatin is associated with reduced cisplatin induced hearing loss. J Clin Invest 2021;131(1).
41.Weijl NI, Elsendoorn TJ, Lentjes EGWM, Hopman GD, Wipkink-Bakker A, Zwinderman AH, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study. Eur J Cancer 2004;40(11):1713-1723.
42.Villani V, Zucchella C, Cristalli G, Galiè E, Bianco F, Giannarelli D, et al. Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial. Head Neck 2016;38:E2118-E2121.
43.Scasso F, Sprio AE, Canobbio L, Scanarotti C, Manini G, Berta GN, et al. Dietary supplementation of coenzyme Q10 plus multivitamins to hamper the ROS mediated cisplatin ototoxicity in humans: A pilot study. Heliyon 2017;3(2).
44.Campbell KC, Rehemtulla A, Sunkara P, Hamstra D, Buhnerkempe M, Ross B. Oral D-methionine protects against cisplatin-induced hearing loss in humans: phase 2 randomized clinical trial in India. Int J Audiol 2022;61(8):621-631.
45. Mukherjea D, Dhukhwa A, Sapra A, Bhandari P, Woolford K, Franke J, et al. Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity. Expert Opin Drug Metab Toxicol 2020;16(10):965-982.
46. Duval M, Daniel SJ. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg 2012;41(5):309-315.
47. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, et al. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm 2021;163:60-71.
48. Freyer DR, Frazier AL, Sung L. Sodium thiosulfate and cisplatin-induced hearing loss. New Engl J Med 2018;379(12):1180-1181.
49. Chen C-, Huang C-, Lin H-H, Wang M-, Chang C-, Cheng Y-. Association of Sodium Thiosulfate with Risk of Ototoxic Effects from Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis. JAMA Network Open 2021.
50. Faber J, Fonseca LM. How sample size influences research outcomes. Dental Press J Orthod 2014;19:27–9.
51. Chauhan RS, Saxena RK, Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose Throat J 2011;90(5).
52. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016;34(23):2712-2720.
53. El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC, Jr., et al. Clinical and genome-wide analysis of cisplatin induced tinnitus implicates novel ototoxic mechanisms. Clin Cancer Res 2019;25(13):4104-4116.
54.Clinicaltrials.gov.Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy[Internet]. 2022 [updated 2022 November 7; cited 2023 January 1]. [1 screen]. ClinicalTrials.gov Identifier: NCT05129748 Available from: https://clinicaltrials.gov/ct2/show/NCT05129748
55. Clinicaltrials.gov.Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity[Internet]. 2022 [updated 2021 July 28; cited 2023 January 1]. [1 screen]. ClinicalTrials.gov Identifier: NCT04817904 Available from: https://clinicaltrials.gov/ct2/show/NCT04817904
56. Clinicaltrials.gov.Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.[Internet]. 2022 [updated 2022 October 25; cited 2023 January 1]. [1 screen]. ClinicalTrials.gov Identifier: NCT04291209 Available from: https://clinicaltrials.gov/ct2/show/NCT04291209
57. Clinicaltrials.gov.Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity[Internet]. 2022 [updated 2022 August 15; cited 2023 January 1]. [1 screen]. ClinicalTrials.gov Identifier: NCT04226456 Available from: https://clinicaltrials.gov/ct2/show/NCT04226456